Datar Genetics Limited

Belkins
Datar Genetics Limited is a NABL and ISO 9001:2008 accredited Centre for Excellence in Genetics for providing innovative, comprehensive clinical management solutions in the domain of molecular genomics. We have fully integrated sequencing, bio-informatics, human interface and interpretation platforms with State of the Art technological capability to provide clinical applications. We provide the widest range of genetic solutions and analytics of 300+ high impact investigations across the domains of Oncology, Cardiology, Neurology, Diabetes, High Resolution HLA Typing and Matching, Reproductive Genetics, Neonatal Screening, Pharmacogenetics and many more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

news image

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

news image

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More

MEDICAL

GENELUX AND NEWSOARA ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR ONCOLYTIC IMMUNOTHERAPIES

Genelux Corporation | September 29, 2021

news image

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Read More

CELL AND GENE THERAPY

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

news image

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More
news image

MEDICAL

KINTOR PHARMA PROVIDES UPDATE ON ONE OF ITS THREE MULTI-REGIONAL PHASE 3 TRIALS OF PROXALUTAMIDE FOR COVID-19

Kintor Pharma | December 29, 2021

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection. Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for testing efficacy and safety of proxalutamide for treating COVID-19 in non-hospitalized COVID-19 patients. At the interim analysis, 348 patients with mild-...

Read More
news image

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More
news image

MEDICAL

GENELUX AND NEWSOARA ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR ONCOLYTIC IMMUNOTHERAPIES

Genelux Corporation | September 29, 2021

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Read More
news image

CELL AND GENE THERAPY

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More